PURE · Pure Bioscience, Inc.
$0.09
+0.01 (+12.64%)
At close · Oct 23
Return incl. dividend (before tax)
Going-concern doubt
— flagged Jun 15, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our history of recurring operating losses, and negative cash flows from operating activities give rise to substantial doubt regarding our ability to continue as a going concern.”View the 10-Q filed Jun 15, 2026
Market Cap
$11.70M
Shares
130.02M
Volume · Oct 23
22.5K
Avg daily vol (3M)
31.87K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.09
Open$0.07
Day$0.07–0.09
52W close$0.04–0.10
Avg vol 30d32K
Short int19K · 0.0% float · 1.0d
Short vol48%
DataJan 2020–Oct 2026
Filing10-Q · Jun 15
Up next
filed Jun 15, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$2.42M
Trailing 12 months
Net income (TTM)
−$2.21M
Trailing 12 months
Revenue growth YoY
+3.5%
Year over year
Operating margin
-79.2%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
−$5.51M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
-0.9%
Year over year · fewer shares
Price change (1Y)
+12.5%
Trailing year
Short interest
0.0%
Latest settlement · 1.0 days to cover
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 19.5 · elevated
Equity put/call 0.67
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+35%
above
Price vs 50-day avg
+24%
above
RSI (14)
60
neutral
MACD trend
Positive
52-week position
83%
mid-range
Momentum
relative strength
1-month return
+29%
trailing
6-month return
+29%
trailing
YTD return
+125%
this year
Relative strength
+23%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +15.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Squeeze score
32
low risk · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
Gross margin
59%
expanding
EPS growth
+33%
Y/Y
Free cash flow
$-2.0M
Balance sheet
$1.3M
net cash
Quant / Vol
risk profile
Volatility
154%
annualized · 1-yr
Max drawdown
−56%
past year
ATR
13.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+35%
Bullish
Price vs 50-day avg
+24%
Bullish
RSI (14)
60
Neutral
MACD trend
Positive
Bullish
52-week position
83%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $0 › 200d $0 — 50d above 200d
Institutional flow
Accumulating
+1 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
0.01% of float · ▲ +15.1% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1 holders — 13F breadth
Price context
position in its 52-week range
Range low $0
Now $0 · 83%
Range high $0
vs 200-day avg +35%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Household & Personal Products — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PURE
this stock
Pure Bioscience, Inc.
|
$11.70M | +125.0% | +12.4% | — | 0.0% |
|
PG
PROCTER & GAMBLE Co
|
$373.21B | +12.4% | +3.3% | 24.3 | 1.1% |
|
UL
Unilever PLC
|
$142.63B | +1.3% | — | — | 0.2% |
|
CL
Colgate Palmolive Co
|
$74.97B | +19.0% | +1.7% | 37.2 | 3.0% |
|
RBGLY
Reckitt Benckiser Group PLC
|
$47.14B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Institutional Holders
Accumulating
Holders
1
- % held
- 0.6%
- Net QoQ
- +809.8K sh
- Top holder
- IFG Advisory, LLC
Held
Float
Short & Settlement
Financials
Filings
SEC Filings
Latest
8-K
- Filed
- Oct 20, 2026
- This year
- 7
PURE BIOSCIENCE, INC. completed a $555,000 private placement on October 15, 2026, issuing 10,183,486 common shares at $0.0545 per share; Mr. Tom Y. Lee invested $555,000 directly and through affiliates.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PURE | +19.7% | +28.6% | +28.6% | +28.6% | +125.0% |
| SPY | -0.4% | -1.5% | +5.8% | -0.4% | +11.5% |
| vs SPY | +20.1% | +30.1% | +22.7% | +28.9% | +113.6% |